Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy
NCT ID: NCT01475877
Last Updated: 2016-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2011-05-31
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK
NCT00347204
Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
NCT01310127
A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief
NCT00330798
Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients
NCT00347503
Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
NCT01847638
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nepafenac
Bromfenac
Bromfenac 0.09% 1 drop in study eyes q day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bromfenac
Bromfenac 0.09% 1 drop in study eyes q day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no other ocular studies with 15 days prior to dosing,
* BCVA 20/200 or better,
* return for study visits and follow instructions from investigator and staff,
* self administer test article
Exclusion Criteria
* hypersensitivity to bromfenac or nepafenac,
* any corneal pathology,
* have had radial keratotomy,
* corneal transplant or corneal refractive surgery in the last two years
21 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Virdi Eye Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Navaneet S Borisuth, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Virdi Eye Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Virdi Eye Clinic and Laser Vision Center
Rock Island, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MAC-02-11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.